September 24, 2023

We are creating some awesome events for you. Kindly bear with us.

A*STAR scientists discover alterations in gene activation of human cancers

Image credits:*STAR

A discovery on the alterations in gene activation of human cancers has been made by scientists from the Agency for Science, Technology and Research (A*STAR)’s Genome Institute of Singapore (GIS).

They have found that these gene alterations take place on a large-scale, where one gene starts from different locations and creates alternate gene products.

This discovery will be pivotal for cancer detection methods, where these gene alterations can detect new biomarkers for projecting the survival rate of a cancer patient and for identifying potential patients for treatments.

To gain a better understanding of these terms and what this all means:

Human genomes contain all our genes. In these genomes, an area called the promoter controls where a gene starts. Its function is akin to a switch, where it “switches on” genes in a genome.

Various genes have more than one promoter which will result in the existence of different functions from the same gene.

Cancer researchers had previously lacked such knowledge on alternating genes and of how their various promoters result in different clinical behaviours of cancer patients.

This prompted them to create a specialised software known as proActiv for identifying activated promoters across genomes. This software was administered to public data of over 18,000 cancer samples through which they found out that the promoters in cancer genes are usually different from those of non-cancer ones.

They also discovered specific activated promoters which are connected to the survival rate of cancer patients and which will serve as a new type of biomarkers.

Dr Andrew Futreal Department Chair of Genomic Medicine at MD Anderson Cancer Center said that this discovery shows that the use of alternate promoters is typical for many forms of cancer.

“These findings will inspire more research into what controls this switching, and how we can use this information to improve outcomes for cancer patients,” he said.

A*STAR has also made other discoveries in the field of cancer treatments.

Scientists from A*STAR’s Institute of Bioengineering and Nanotechnology (IBN) had discovered an advanced nanocarrier for delivering anti-cancer drugs in the desired manner.

They created a compatible nanocarrier, which is derived from green tea catechins, for the anti-cancer drug for kidney cancer, Sunitinib (SU).

Green tea contains an antioxidant known as epigallocatechin-3-O-gallate (EGCG) which can stop cancer when administered in large doses.

This greatly improved the performance of the anti-cancer drug during experiments for hindering the growth and spread of tumours, while significantly reducing the levels of toxicity which are typical of the treatment procedures.

  1. Low-drug loading capacities

Nanocarriers usually have a low drug-loading capacity. This will result in the need for increasing the dosage or the rate of administering the drugs to meet the intended treatment results. The potential harms as a result of this are the rise in toxicity levels and other side effects.

  1. Elevating drug-loading runs

This will result in the instability of the nanocarrier and thus resulting in low efficiency and affect toxicity levels as well.

To avoid the above scenarios, the nanocarriers were developed with essential therapeutic properties, supplementing the anti-cancer drug’s efficiency and reducing the importance of the drug-to-carrier ratio.

Recommended Stories


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend